IONS
SHORT CANDIDATEMeanRevComposite
23.90
Technical
0.50
Fundamental
31.70
Rank
—
Price
54.49
Hurst
0.38
As of
Aug 4, 2026
Daily
Ionis Pharmaceuticals, Inc.
HealthcareBiotechnologyIonis Pharmaceuticals is a biotechnology firm that develops and markets RNA-targeted therapies for rare genetic and neurological disorders. The company sells several approved medications including treatments for spinal muscular atrophy, hereditary angioedema, amyloidosis-related nerve damage, and ALS, among other conditions. Ionis maintains a pipeline of experimental drugs in various development stages and has partnerships with major pharmaceutical companies including Biogen, GSK, AstraZeneca, Novartis, and Roche.
Market cap
$7.8B
P/E (trailing)
—
P/E (forward)
-42.03
PEG ratio
27.33
Dividend yield
—
Beta
0.42
52w range
44.66 – 86.74
Return on equity
-105.50%
Profit margin
-64.66%
Revenue growth
-40.70%
Earnings growth
—
Price history
1Y: 44.84 (-27.4%) · range 44.84–86.50
Cycle position
7/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 85 · STRONG SETUP · exit proximity 0
Conviction
45/ 100 · maturity 100%
VScore.4017
Buildup.2062
EMA entry setup.2585
Fundamentals.1532
Volume profile
POC
75.38
Price vs POC
-40.5%
Overhead supply
100%
Runway
+21.2%
Value area 55.60–82.53 · 100% of 120d volume overhead · heavy supply
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| breakdown-signal | 0.198 | Sep 16, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +1.08% | +14.71% | mature |
| 40d | -2.18% | +14.71% | 22/40d |